Concord Biotech Ltd
Ticker: CONCORDBIO
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1507.50
Market Cap
15770.89
Debt/Equity
0.0016
ROE %
22.259
PB
8.7001
Promoter %
44.082
Pledge %
0.000
1Y Rev Growth %
18.068
5Y Rev Growth %
18.007
NP Margin %
29.863
NP Margin 5Y Avg %
29.428
Trading Reference
1M Return %
-7.800
6M Return %
-13.017
1Y Return %
-22.077
% Away 52W High
62.633
% Away 52W Low
12.082
Daily Volume
198073
Investment Verdict
Hold
Score 64/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Concord Biotech Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If it breaks above the resistance level, there is potential for significant upside. However, if it falls below the support, downside risk increases.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
C
Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
View details
T
Triveni Turbine Ltd
Triveni Turbine Ltd shows potential in a growing sector with decent financial metrics, but faces challenges in profitability consistency and valuation concerns.
View details
J
JBM Auto Ltd
JBM Auto Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
T
Travel Food Services Ltd
Travel Food Services Ltd faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
A
Aditya Infotech Ltd
Aditya Infotech Ltd shows potential in a growing sector but faces challenges in consistent growth and profitability. Caution is advised due to execution risks and market sentiment.
View details
C
Choice International Ltd
Choice International Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
S
Sobha Ltd
Sobha Ltd shows potential for growth but faces several risks that could impact its performance.
View details
T
Techno Electric & Engineering Company Ltd
Techno Electric & Engineering Company Ltd shows potential in a future-ready sector but faces challenges in growth consistency and valuation metrics.
View details
R
RBL Bank Ltd
RBL Bank Ltd shows potential but faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
R
Ratnamani Metals and Tubes Ltd
Ratnamani Metals and Tubes Ltd shows decent potential with stable growth, but investors should be cautious of profitability fluctuations and execution risks.
View details
A
Aptus Value Housing Finance India Ltd
Aptus Value Housing Finance shows potential for growth, but faces challenges in valuation and execution risks.
View details
G
Gallantt Ispat Ltd
Gallantt Ispat Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
T
Tbo Tek Ltd
Tbo Tek Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
A
Afcons Infrastructure Ltd
Afcons Infrastructure Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and execution risks.
View details
N
Netweb Technologies India Ltd
Netweb Technologies India Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
G
Godawari Power and Ispat Ltd
Godawari Power and Ispat Ltd shows potential in a future-ready sector but faces challenges in growth consistency and market sentiment.
View details
Business Overview
Concord Biotech Ltd is a leading biopharmaceutical company based in India, specializing in the development and manufacturing of high-quality biopharmaceuticals. Catering to global markets, it focuses on producing biosimilars and innovative therapies, primarily for oncology and autoimmune diseases. The company's commitment to research and development ensures it remains at the forefront of biotechnological advancements. With a strong regulatory compliance track record, Concord Biotech is trusted by healthcare professionals and patients alike, making it a significant player in the biopharma sector.
- Leading biopharmaceutical company in India
- Specializes in biosimilars and innovative therapies
- Focus on oncology and autoimmune diseases
- Strong commitment to research and development
- Trusted by healthcare professionals globally
- Robust regulatory compliance and quality standards
Investment Thesis
Concord Biotech Ltd stands out due to its credible promoter group, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company for sustainable growth, making it a compelling investment opportunity for retail investors seeking long-term value.
- Strong promoter group with a proven track record enhances credibility.
- Significant growth potential in digital services sector.
- Attractive valuation metrics compared to industry peers.
- Focus on innovation and R&D supports future expansion.
- Solid financial performance indicates resilience and stability.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Growing demand for biotech solutions
- Strategic partnerships with major firms
- Expanding global market presence
Risks ⚠️
- Regulatory hurdles in drug approvals
- High competition in biotech sector
- Dependence on a few key products
- Market volatility affecting stock price
Peer Perspective
Concord Biotech Ltd trades at a slight premium to peers like Biocon and Dr. Reddy's, driven by its robust growth prospects; however, a sustained improvement in margin stability is crucial for further rerating.
Future Outlook
Concord Biotech Ltd is well-positioned for growth, driven by its robust pipeline and market expansion. Success will depend on effective execution and cost control to navigate industry challenges.
AI FAQs for Retail Users
- Q: What does Concord Biotech Ltd do?A: Concord Biotech Ltd specializes in biotechnology, focusing on developing and manufacturing biopharmaceuticals.
- Q: Is Concord Biotech Ltd a profitable company?A: The company's financial performance can vary; check recent earnings reports for current profitability.
- Q: What are the risks of investing in Concord Biotech Ltd?A: Risks include market volatility, regulatory changes, and competition in the biotech sector.
- Q: How can I buy shares of Concord Biotech Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: What is the outlook for the biotech industry in India?A: The biotech industry in India shows growth potential, driven by innovation and increasing healthcare needs.
📊 Stock Investment Checklist (100 Points)
Concord Biotech Ltd • Updated: 2025-09-17 01:45:26
-
10BusinessHighThe biotech sector is promising, but competition is intense.
-
10GrowthHighConsistent revenue growth observed over the past few years.
-
10ProfitabilityHighROE and ROCE are healthy, but cash flow is inconsistent.
-
8ValuationHighP/E ratio is higher than industry average, indicating overvaluation.
-
7BalanceHighModerate debt levels with adequate liquidity.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Concord Biotech Ltd shows potential for growth but faces challenges in valuation and execution risks.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 80/100
- Profitability: 70/100
- Governance: 65/100
- Market Confidence: 72/100